← Tra cứu cổ phiếu

iShareInvest Research

HOSE · Quý 2/2026

DBD

Dược - Trang thiết bị Y tế Bình Định (Bidiphar)

Analysis of business results & financial statements · Quý 2/2026

▼ Under pressure

Trailing net profit reached 288.9bn, fell 18.1bn compared with the same period last year. Key positives came from lower administrative expenses, higher financial income, better other profit, and lower tax. Offsetting pressure came mainly from lower gross profit, lower associates income, higher selling expenses, and higher deferred tax. Detailed impact is shown below:

See what is changing ↓
P/E
15.20x
P/B
2.53x
EPS
3,056
BVPS
18,375
ROE
17.1%
ROA
11.1%
Market price
46,450
16 Oct 2026

What Is Changing

On a TTM 2026Q2 basis, DBD is declining across multiple metrics versus the same period, suggesting current pressure is not coming from just one side — profit is near a multi-period low. What remains unclear is whether the business can stabilize before this trend deepens.

Profit bridge

Vs last year · TTM

  1. Administrative expenses
  2. Financial income
  3. Other profit
  4. Tax
  5. Gross profit
  6. Associates income
  7. Selling expenses
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 2/2026

MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue471.7448.1510.0439.7474.5441.0477.9432.8
LNST89.280.359.559.990.381.060.675.0
Net margin18.91%17.92%11.67%13.63%19.04%18.37%12.69%17.33%

Revenue

472bn

Net income

89bn

Net margin

18.91%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins narrowed but earnings quality remains clean — pressure is mainly operational.

Revenue Growth

●

Is growth real and durable?

Trailing-12-month revenue grew 2.4% year on year — but the quarterly pace is slowing (+2% → −1%).

3 of the last 4 quarters grew year on year.

Revenue TTM
1,869bn
+2.4%
Latest quarter YoY
−1%
slowing

What is driving the margin?

▼

Net margin narrowed to 15.45%, falling 1.4pp. The main pressure is Gross margin fell 4.4pp, outweighing the improvement in SG&A / Revenue fell 2.7pp (with additional support from Net financial result / Revenue rose 0.9pp and Other profit / Revenue rose 0.2pp).

The pressure comes from core operations — this is a concerning type of decline, not a one-off movement.

Net Margin
15.45%
−1.4pp
Gross Margin
44.96%
−4.4pp
SG&A / Revenue
28.39%
−2.7pp

TTM YoY · 2025Q2 -> 2026Q2

Cash Flow

▼▼

Is profit converting into cash?

With leverage safe, cash flow shows the self-funding capacity. Operating cash flow reached 615.2bn against investing cash flow of -661.6bn (annual cash-flow figures for 2025).

Post-investment cash flow was negative +46.4bn. Financing cash flow was negative +65.0bn.

CFO / net income was 1,29 lần.

After spending +416.6bn on fixed-asset investment, the business generated trailing free cash flow of −43.4bn.

Earnings Quality

▲

How much income is non-core?

About 94% of pre-tax profit comes from core operations.

Within that, net financial result at +5.2%, other profit at +0.4% of PBT.

Non-core / PBT
5.6%
low
Net financial / PBT
5.2%
Other profit / PBT
0.4%
02

Is capital being used efficiently?

Capital efficiency is declining — check whether the drag is from margins or turnover.

Is capital being deployed efficiently?

▼▼

ROIC fell to 18.14%, losing 3.5pp. That translates to 18.14 in after-tax operating profit for every 100 units of operating capital. Both NOPAT margin narrowed 1.6pp and capital turnover fell 0.10x, while invested capital rose by 161bn — pressure came from both operational efficiency and asset efficiency.

Both margin and turnover weakened — this is a broad-based decline, and cyclical versus structural components need to be separated.

Working Capital Efficiency

▲▲

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 29.5 days versus the same period last year. The main moves came from DIO fell 13.2 days, DSO fell 1.1 days, and DPO rose 15.3 days.

All 3 drivers (collection, inventory, payables) are improving — working capital turnover is strengthening across the board.

Cash conversion cycle remains stretched

CCC stands at 225.2 days, suggesting that working capital remains tied up for a relatively long operating cycle.

DuPont

What drives ROE?

Net margin 15.5% -1.4pp
Asset turnover 0.72x -0.11x
Financial leverage 1.54x +0.16x
ROE 17.1% -2.0pp

ROE fell from 19.1% to 17.1% — dragged by asset turnover and net margin together, though leverage still provided support.

03

Is financial risk significant?

Leverage is safe but FCF is negative at 43.4bn due to capex of 416.6bn — an investment choice, not an urgent risk.

Leverage & Liquidity

▲

Leverage looks fairly comfortable, with net debt / equity at 0.04x and interest coverage at 21.45x.

At present, short-term debt accounts for 12.1% of total debt, cash equals 72.1% of debt, and total debt stands at 257.1bn.

Net Debt / Equity
0.04x
+0.19x
Interest Coverage
21.45x
−2.05x
Cash / Debt
72.1%
−411.7pp
Short-term Debt / Total Debt
12.1%
−57.1pp

TTM YoY · 2025Q2 -> 2026Q2

Balance Sheet

▲

The balance sheet shows capital-allocation efficiency slipping. Capital structure is conservative with low leverage — liabilities at 0.50x equity, net debt at 0.04x equity.

Inventory ended the period at 366.1bn, roughly 14.1% of total assets.

Over the last 12 months, working capital released 94.1bn of cash, mainly thanks to lower receivables and higher payables. Pressure from higher inventories only partly offset that benefit.

Research synthesis

What this reporting period is showing

The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is earnings conversion is confirmed, with CFO/NI at 1.29x. The main risk still sits in working capital is tied up too long in the operating cycle, with CCC extended to 225 days.

  • Improvement: earnings conversion looks more confirmed, with CFO / net income at 1.29x.
  • Key risk: working capital remains tied up for too long, with cash cycle at 225.2 days.

Questions for the next period

  1. Whether revenue sustains its +2,4% YoY pace or begins to slow.

  2. Whether margins hold around the current 15.45% level or narrow again.

  3. Whether operating cash flow holds its 615.2bn (cumulative for 2025) level in upcoming periods or weakens.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio